Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

Cancer Epidemiology

Volumn 36, Issue 6, 2012, Pages

  Pinsky, Paul F ^a   Black, Amanda ^a   Parnes, Howard L ^a   Grubb, Robert ^b   David Crawford, E ^c   Miller, Anthony ^d   Reding, Douglas ^e   Andriole, Gerald ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e MARSHFIELD CLINIC   (United States)

Author keywords

Gleason grade; Prostate cancer; PSA; Screening; Survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; DISEASE SPECIFIC SURVIVAL; DISEASE SURVEILLANCE; HEALTH PROGRAM; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL RATE;

AGED; DIGITAL RECTAL EXAMINATION; EARLY DETECTION OF CANCER; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84868301227     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2012.08.008     Document Type: Article

References (15)

1. Andriole G.A., Crawford E.D., Grubb R., Buys S., Chia D., Church T.R., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360:1310-1319.
2. Schroder J.H., Hugossan J., Roobol M.J., Tammela T., Ciatto S., Nelen V., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
3. Andriole G.L., Crawford E.D., Grubb R., Buys S., Chia D., Church T.R., et al. Screening for prostate cancer, 13-year update of the results of the prostate component of the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. J Natl Cancer Inst 2012, 104:1-8.
4. Croswell J.M., Ransohoff D.F., Kramer B.S. Principles of cancer screening: lessons from history and study design issues. Semin Oncol 2010, 37:202-215.
5. Prorok P., Andriole G.L., Bresalier R.S., Buys S., Chia D., Crawford E.D., et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000, 21:273S-309S.
6. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
7. Surveillance Research Program, National Cancer Institute SEER* Stat software () version 6.5.1 (accessed July, 2011). http://www.seer.cancer.gov/seerstat.
8. Lin D.W., Porter M., Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer. Cancer 2009, 115:2863-2871.
9. Pinsky P.F. Antioxidant supplementation and cancer prevention. J Am Med Assoc 2009, 301:1878.
10. Pinsky P.F., Black A., Kramer B.S. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Clin Trials 2010, 7:303-311.
11. Schroder F.H., Hugosson J., Roobol M.J., Tammela T., Ciatto S., Nelen V., et al. Prostate-cancer mortality at 11 years follow-up. N Engl J Med 2012, 366:981-990.
12. Pinsky P.F., Miller A., Kramer B.S., Church T., Reding D., Prorok P., et al. Evidence of a healthy volunteer effect in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Am J Epidemiol 2007, 165:874-881.
13. Sheridan T.B., Carter H.B., Wang W., Landis P.B., Epstein J.I. Change in prostate cancer grade over time in men followed expectantly for Stage T1c disease. J Urol 2008, 179:901-905.
14. Choo R., Danjoux C., Morton G., Szumacher E., Sugar L., Gardner S., et al. How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7 clinically localized prostate cancer?. Prostate 2007, 67:1614-1620.
15. D'Amico A.V., Whittington R., Malkowicz S.B., Weinstein M., Tomaszewski J.E., Schultz D., et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001, 166:2185-2188.